ALX Oncology Announces November Investor Conference Participation
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) announced its participation in two upcoming investor conferences in November 2024. The company will participate in the UBS Global Healthcare Conference on November 12 at 3:30 PM PST in Rancho Palos Verdes, CA, featuring a fireside chat with analyst Trung Huynh. Additionally, they will attend the Jefferies London Healthcare Conference on November 19 at 9:00 AM GMT in London, with analyst Michael Yee. Both events will include 1x1 meetings and webcasts accessible through ALX Oncology's website, with replays available for up to 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ALXO gained 2.76%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that management will participate in two upcoming investor conferences.
2024 UBS Global Healthcare Conference
Format: Fireside chat with analyst, Trung Huynh, and 1x1 meetings
Date: Tuesday, November 12
Time: 3:30 PM PST
Location: Rancho Palos Verdes, CA
Webcast link: Available here
2024 Jefferies London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee, and 1x1 meetings
Date: Tuesday, November 19
Time: 9:00 AM GMT
Location: London, UK
Webcast link: Available here
The live webcasts for the UBS and Jefferies fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
When is ALX Oncology (ALXO) presenting at the UBS Global Healthcare Conference 2024?
When is ALX Oncology (ALXO) presenting at the Jefferies London Healthcare Conference 2024?
How long will ALX Oncology's (ALXO) conference webcasts be available for replay?
